N-(3-bromophenyl)cinnamamide | 349426-35-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: N-(3-bromophenyl)cinnamamide
• CAS: 349426-35-3
• 化学式: C₁₅H₁₂BrNO
• 分子量: 302.16
• InChiKey: IHWKXVBHNSPIGD-UHFFFAOYSA-N

物化性质

• 沸点：
  470.9±45.0 °C(Predicted)
• 密度：
  1.455±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(3-bromophenyl)cinnamamide 在 aluminum (III) chloride 、 氯苯 作用下， 生成 7-溴喹啉-2(1H)-酮 、 5-溴-1H-喹啉-2-酮
  参考文献：
  名称：

  HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT

  摘要：

  揭示了一种新颖的杂环双芳基衍生物，可用作药物，并表现出磷酸二酯酶抑制作用。这些杂环双芳基衍生物由以下一般式（1）表示： 其中杂环1和杂环2直接连接在一起。

  公开号：

  US20110178041A1

文献信息

• DDQ-promoted direct transformation of benzyl hydrocarbons to amides via tandem reaction of the CDC reaction and Beckmann rearrangement
  作者：Jun Qiu、Ronghua Zhang

  DOI：10.1039/c3ob41218k

  日期：——

  An atom-efficient and transition metal-free approach to amides from the corresponding benzyl hydrocarbons through C–H and C–C bond cleavage has been developed. Mechanistic studies have shown that a DDQ-promoted cross-dehydrogenative coupling (CDC) reaction with subsequent oxidation and rearrangement are involved in this transformation.

  开发了一种通过C-H和C-C键断裂，从相应的苄基烃高效、无需过渡金属的原子到酰胺合成的方法。机理研究表明，这种转化涉及DDQ促进的交叉脱氢偶联（CDC）反应、随后氧化和重排。
• Synthesis, SAR and in vivo activity of novel thienopyridine sulfonamide pyrrolidinones as factor Xa inhibitors
  作者：Michael R. Becker、William R. Ewing、Roderick S. Davis、Henry W. Pauls、Cuong Ly、Aiwen Li、Helen J. Mason、Yong Mi Choi-Sledeski、Alfred P. Spada、Valeria Chu、Karen D. Brown、Dennis J. Colussi、Robert J. Leadley、Ross Bentley、Jeff Bostwick、Charles Kasiewski、Suzanne Morgan

  DOI：10.1016/s0960-894x(99)00466-7

  日期：1999.9

  Thienopyridine sulfonamide pyrrolidinones were found to be potent and selective inhibitors of the coagulation cascade enzyme factor Xa. SAR studies led to several compounds that were selected for further in vivo investigation. These novel aryl binding pocket moieties represent a structural modification to a series of fXa inhibitors. Several compounds proved to be efficacious i.v. antithrombotic agents

  发现噻吩并吡啶磺酰胺吡咯烷酮是凝血级联酶因子Xa的有效和选择性抑制剂。SAR研究导致选择了几种化合物进行进一步的体内研究。这些新颖的芳基结合口袋部分代表了一系列fXa抑制剂的结构修饰。几种化合物被证明是有效的静脉抗血栓药。
• 2-QUINOLINONE AND 2-QUINOXALINONE-DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS
  申请人：Godfrey Andrew Aydon

  公开号：US20120270864A1

  公开（公告）日：2012-10-25

  The present invention relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation.

  本发明涉及公式(I)化合物及其药学上可接受的盐，以及它们在治疗细菌感染方面的用途和制备方法。
• COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS
  申请人：Breault Gloria

  公开号：US20110092495A1

  公开（公告）日：2011-04-21

  The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

  本发明涉及表现出抗菌活性的化合物，其制备过程，含有它们作为活性成分的制药组合物，它们作为药物的使用以及它们在制造用于治疗温血动物（如人类）细菌感染的药物中的使用。特别是本发明涉及用于治疗温血动物（如人类）细菌感染的有用化合物，更具体地涉及这些化合物在制造用于治疗温血动物（如人类）细菌感染的药物中的使用。
• Compounds for the treatment of multi-drug resistant bacterial infections
  申请人：AstraZeneca AB

  公开号：EP2289890A1

  公开（公告）日：2011-03-02

  The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

  本发明涉及具有抗菌活性的化合物、制备这些化合物的工艺、含有这些化合物作为活性成分的药物组合物、这些化合物作为药物的用途以及这些化合物在制造用于治疗温血动物（如人类）细菌感染的药物中的用途。特别是本发明涉及用于治疗温血动物（如人类）细菌感染的化合物，尤其是涉及这些化合物在制造用于治疗温血动物（如人类）细菌感染的药物中的用途。